Machine learning algorithm can help predict progression of age-related macular degeneration

Scientists have demonstrated that a machine learning algorithm, using images of patients' retinas obtained over time, can predict the critical moment when early or intermediate age-related macular degeneration (AMD) will progress into severe AMD. The research is being presented during a press conference at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, Md, on Monday, May 8 from 9:30 – 10:15 am.

After gathering optical coherence tomography (OCT) images of 38 patients' retinas with early/intermediate AMD -; every three months for a minimum of 15 months -; researchers used the algorithm to accurately predict the occurrence of drusen regression within the next 12 months. While the presence of lipid/protein deposits called drusen is the hallmark of early/intermediate age-related macular degeneration (AMD), their sudden regression is strongly associated with the onset of late AMD.

Currently, there are no treatments for early/intermediate AMD. Anti-VEGF treatments for late AMD can prevent disease progression, but only after some vision loss has occurred. By pinpointing the moment of transition from early/intermediate to late AMD, the researchers state that machine learning will substantially contribute to the development of new therapeutics that target slowing AMD progression.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation